Plain-English translation of NCT06519760 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new imaging scan called PET/CT that may help doctors detect clear cell kidney cancer more accurately. The scan works by targeting a protein called CAIX that appears in about 95% of clear cell kidney cancers. Researchers will compare how well this new scan performs compared to a standard imaging scan (called 18F-FDG PET/CT) that is already used in clinical practice.
Currently, doctors sometimes have difficulty determining whether a kidney mass is cancer or something harmless, and they need better tools to diagnose and monitor kidney cancer. This trial exists to see if the new imaging method can provide clearer, more accurate pictures that help doctors make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will receive an intravenous injection of the new imaging agent and then undergo a PET imaging scan. Within one week, you will also have a whole-body standard PET scan (18F-FDG PET/CT). Both scans are non-invasive procedures where you lie still while imaging equipment takes pictures of your body. The study involves 200 patients total and is being conducted at Peking University First Hospital in China.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China